Literature DB >> 18035862

Biotherapeutics in the era of biosimilars: what really matters is patient safety.

Paul J Declerck1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18035862     DOI： 10.2165/00002018-200730120-00002

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  1 in total

Review 1.  Follow-on biologics: challenges of the "next generation".

Authors:  Huub Schellekens
Journal:  Nephrol Dial Transplant       Date:  2005-05       Impact factor: 5.992
  1 in total
  3 in total

1.  Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.

Authors:  Niels S Vermeer; Sabine M J M Straus; Aukje K Mantel-Teeuwisse; Francois Domergue; Toine C G Egberts; Hubert G M Leufkens; Marie L De Bruin
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

Review 2.  Biosimilar agents in oncology/haematology: from approval to practice.

Authors:  Dietger Niederwieser; Stephan Schmitz
Journal:  Eur J Haematol       Date:  2011-01-25       Impact factor: 2.997

Review 3.  Etanercept biosimilars.

Authors:  Valderilio F Azevedo; Nathalia Galli; Alais Kleinfelder; Julia D'Ippolito; Paulo C M Urbano
Journal:  Rheumatol Int       Date:  2014-07-01       Impact factor: 2.631
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.